Greenwich LifeSciences (NASDAQ:GLSI) added ~23% in the premarket on Wednesday after the company posted preliminary immune ...

Greenwich LifeSciences, Inc. STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on ...

Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for ...

The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both HLA-A*02 and non-HLA-A*02 arms. The non-HLA ...

(RTTNews) - Greenwich LifeSciences, Inc. (GLSI) Wednesday reported preliminary positive immune response data from FLAMINGO-01 Phase 3 study evaluating GLSI-100, an immunotherapy to prevent breast ...

STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial ...

Greenwich LifeSciences, Inc. provided an update on its Phase III clinical trial, FLAMINGO-01, which is investigating the immunotherapy GLSI-100 for preventing breast cancer recurrences.

These two general immune response findings, immune response at baseline and increasing immune response over time, were also observed in the Phase IIb clinical trial for HLA-A*02 only patients. These ...

Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types (non- HLA-A*02), show that GLSI-100 is creating an immune response over ...